Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 5.4% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a company specializing in treatments for neurodegenerative diseases. Today, the stock showed significant bullish movement in the market.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 5.4% on Dec 23, 2025 14:42

• Despite a recent downgrade to a "sell" rating, several brokerages have increased price targets and maintained a consensus "Moderate Buy" rating on AMLX.
• The company surpassed earnings per share (EPS) expectations, although insider selling and ongoing legal proceedings by Rosen Law Firm could have led to stock volatility.
• Investors appear to be responding favorably to the company's performance amid legal challenges, possibly reflecting confidence in its future prospects within the neurodegenerative disease treatment market.
• Various factors, including financial results, analyst evaluations, legal matters, and general sentiment towards the biotech industry, may have contributed to the market movement.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen

Amylyx Pharmaceuticals (NASDAQ:AMLX) received a "sell" rating downgrade from Wall Street Zen, contrasting with multiple brokerages that have raised price targets and a consensus "Moderate Buy" rating from MarketBeat. Despite beating recent EPS expectations, insiders sold a significant number of shares, while institutional and hedge fund ownership remains high. The company, focused on neurodegenerative disease treatments, has a market capitalization of $1.32 billion.

https://www.marketbeat.com/instant-alerts/amylyx-pharmaceuticals-nasdaqamlx-lowered-to-sell-rating-by-wall-street-zen-2025-12-20/

AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Rosen Law Firm is reminding investors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) who purchased securities between November 11, 2022, and November 8, 2023, about an April 9, 2024, deadline to join a securities class action lawsuit. The lawsuit alleges that Amylyx Pharmaceuticals made false or misleading statements regarding the commercial prospects and prescription rates of its ALS drug, RELYVRIO, and asks investors with losses exceeding $100K to secure counsel. Investors may be entitled to compensation without out-of-pocket fees.

https://www.newsfilecorp.com/release/204062

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.2% Today

Ethena ($ENA) Crypto Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.0% Today

Pepe ($PEPE) Crypto Forecast: Up 6.2% Today

Chiliz ($CHZ) Crypto Forecast: Up 5.3% Today

Republic Services Inc. ($RSG) Stock Forecast: Down 1.3% Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.7% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

Amylyx Pharmaceuticals Price History

27.07.2025 - AMLX Stock was up 5.1%

• AMLX stock surged as investors reacted positively to the company's strategic shift in focus from AMX0035 to avexitide and amyotrophic lateral sclerosis programs.
• The decision to halt the Phase 2b trial for AMX0035 in progressive supranuclear palsy, despite showing no benefit over placebo, was seen as a prudent move by the company to reallocate resources to more promising programs.
• The announcement of a cash runway through 2026 provided investors with confidence in the company's long-term sustainability and growth potential, contributing to the bullish sentiment surrounding AMLX stock today.

25.05.2025 - AMLX Stock was up 9.2%

• AMLX displayed significant bullish movement in the market today.
• The upward trend can be attributed to optimistic analyst views regarding the company's potential PBH treatment, which is estimated to target a $2 billion global market by 2035.
• Investor enthusiasm is likely fueled by the anticipation of Avexitide's Phase 3 trial results in the first half of 2026 and the positive outcomes seen in Phase 2 trials.
• Positive analyst initiations and coverage have also played a role in fostering a favorable outlook on AMLX, signaling increasing confidence in the company's future prospects.

14.06.2025 - AMLX Stock was up 5.3%

• AMLX stock surged due to positive results from the Phase 2b trial of their drug avexitide, which showed a significant reduction in hypoglycemic events post-weight loss surgery.
• The promising data from the trial likely boosted investor confidence in the drug's potential success in the market, leading to the bullish movement in AMLX stock.
• The positive news overshadowed other market events such as the drop in PPI and Industrial Production, indicating that investors were primarily focused on the favorable trial results of avexitide.

10.11.2025 - AMLX Stock was down 5.1%

• The recent Phase 1 LUMINA trial showed positive safety and tolerability data for AMX0114 in ALS patients, which was anticipated to boost Amylyx Pharmaceuticals.
• However, investors seemed underwhelmed, possibly expecting more significant efficacy results rather than just safety and tolerability data.
• Market sentiment may be cautious due to uncertainty surrounding upcoming biomarker data from the first cohort, expected in the first half of 2026.
• The current bearish trend could indicate a "sell the news" attitude, with investors waiting for stronger clinical outcomes before driving up the stock price.

23.11.2025 - AMLX Stock was up 5.4%

• Despite a recent downgrade to a "sell" rating, several brokerages have increased price targets and maintained a consensus "Moderate Buy" rating on AMLX.
• The company surpassed earnings per share (EPS) expectations, although insider selling and ongoing legal proceedings by Rosen Law Firm could have led to stock volatility.
• Investors appear to be responding favorably to the company's performance amid legal challenges, possibly reflecting confidence in its future prospects within the neurodegenerative disease treatment market.
• Various factors, including financial results, analyst evaluations, legal matters, and general sentiment towards the biotech industry, may have contributed to the market movement.

06.10.2025 - AMLX Stock was down 5.1%

• The bearish movement in AMLX could be attributed to a class action lawsuit against the company for securities fraud, likely causing uncertainty and negative sentiment among investors.
• Concerns about the lawsuit's impact on the company's financial stability and reputation may have led to a sell-off of the stock.
• An ongoing investigation into the claims against AMLX could have intensified pressure on the stock price, as uncertainty typically results in reduced investor confidence and a decline in stock value.

10.10.2025 - AMLX Stock was down 5.0%

• AMLX stock might have experienced a bearish movement due to a securities fraud class action investigation by Grabar Law Office, causing uncertainty and negative sentiment among investors.
• The investigation and potential legal implications could have led to a lack of confidence in the company's management and financial practices, resulting in a sell-off of AMLX shares.
• Investors may be concerned about the impact of the ongoing legal issues on the company's future performance and profitability, leading to a bearish trend in the stock price.

08.11.2025 - AMLX Stock was down 5.4%

• Positive safety and tolerability data from the Phase 1 LUMINA trial for AMX0114 in ALS did not immediately boost AMLX as expected.
• Market response was bearish, possibly due to investors anticipating more substantial efficacy results rather than safety and tolerability data alone.
• Disappointment may have arisen from the delay in biomarker data release, now expected in the first half of 2026.
• Despite the encouraging trial outcomes, market sentiment seems cautious about the potential of AMX0114 in treating ALS, contributing to the recent bearish trend.

17.09.2025 - AMLX Stock was down 5.0%

• The strong bearish movement in AMLX stock today could be attributed to profit-taking by investors after a period of solid earnings estimate revision activity.
• Despite belonging to a strong industry, the stock may have faced selling pressure due to market volatility or broader economic concerns.
• Investors might be reassessing their positions in AMLX stock, leading to a temporary decline in its market value.

24.05.2025 - AMLX Stock was up 10.1%

• Amylyx Pharmaceuticals (NASDAQ: AMLX) experienced a strong bullish movement today.
• The upsurge in the stock's performance may be linked to a new analyst initiating a favorable outlook on the company.
• Analyst Marcus Cole from UBS commencing coverage on a positive note possibly bolstered investor confidence in AMLX.
• The optimistic analyst outlook likely played a role in driving the bullish momentum in AMLX's stock price during the day.

05.10.2025 - AMLX Stock was down 4.1%

• An investigation into claims of securities fraud might have affected investor confidence in the company's operations and financial reporting.
• The survival of the class action lawsuit could lead to legal and financial challenges for Amylyx Pharmaceuticals, creating uncertainty for investors.
• Negative developments surrounding the company may have dampened market sentiment, overshadowing potential growth prospects and contributing to the bearish movement.

15.11.2025 - AMLX Stock was down 5.1%

• The decline in AMLX's market performance today might be due to profit-taking by corporate insiders amidst recent negative sentiment and selling activity.
• Concerns raised about AMLX potentially being overvalued, evident in its price-to-book ratio surpassing the industry average, could have contributed to the selling pressure.
• Investors' reaction to the warning of possible setbacks in trials that might dampen the current optimism surrounding AMLX could have prompted today's bearish market movement.